


UPDATE ON TOLVAPTAN (JINARC®)



The HSE introduced a managed access protocol (MAP) for tolvaptan (Jinarc®) in February 2020. The aim of the MAP is to provide patients with autosomal dominant polycystic kidney disease, with chronic kidney disease (CKD) stage 2 or 3 and evidence of rapidly progressing disease, with access to tolvaptan (Jinarc®).

To date, the HSE have approved twelve prescribers for tolvaptan (Jinarc®) under this protocol. The majority of applicants (86%) were CKD stage 3 at the time of application. Twenty-one patients received treatment in June 2023 with a total of 27 patients having initiated treatment since introduction of the MAP.

July 2023

HSE Medicines Management Programme.